A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.

Nat Commun · 2018 · PMC5915573 · PMID 29691399

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Combination of both of these factors had higher AUC than the 4-miRNA signature or metastatic site alone in all the thee cohorts, although the difference did not reach statistical significance (Fig. 4d–f ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.